Table 3.
The patient demographical, and laboratory outcomes during the hospital stay
| Age (yrs), sex, race/ethnicity, location, BMI. | Underlying medical conditions | Clinical signs and symptoms | Previous respiratory illness/SARS-CoV-2 testing | SARS-CoV-2 testing at time of MIS-A admission | Imaging/Other diagnostic studies | Treatments | Outcome and length of stay | Screened microorganisms | Laboratory findings | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 43-year old, male, caucasian , BMI:26 kg/m2 | None | Fever, weakness, joint pain, abdominal pain, headache, redness eyes, skin lesions | Self isolation between Apr 13-24, 2021, COVID 19 PCR (-) on Apr 13, 2021 | PCR (-) on Jun 7-9, 2021; Antibody test (+) on Jun 10 2021 | Thorax CT: Normal; Abdominal CT:Normal; Abdominal ultrasonography: grade 1 hepatosteatos; at initial admission:[ECHO EF:60, ECG; negative T and non-specific ST-T segmental changes (V1-V6 )]At the discharge [ECHO: EF 64% and normal ECG.] | Steroid, IVIG, and LMWH | Disovered completely, and discharged at 14th of the treatment | Multiple blood cultures | N | C-reactive protein( < 5 mg/L) | 144* |
| Urine culture | N | D-dimers ( < 500 µg/L) | 2033* | ||||||||
| Rectal swab for multi-drug resistant bacteria | N | Ferritin (30-400 µg/L) | 3978* | ||||||||
| HBV and HCV | N | Lactate dehydrogenase (135-225 U/L) | 589* | ||||||||
| Leptospira | N | White blood count (4.5-10.5x10^9/L) | 11.7* | ||||||||
| Borrelia burgdorferi | N | Neutrophil count ( 45-78 %) | 85.5* | ||||||||
| SARS-CoV-2 (PCR) | N | Lymphocyte count (1.32-3.57x10^9/L) | 0.74** | ||||||||
| SARS-CoV-2 (Antibody test) | P | Platelet count (150–400x10^9/L) | 78** | ||||||||
| CMV IgG | P | Creatinine (07-1.2mg/dl) | 0.9* | ||||||||
| CMV IgM | N | Troponin T(0.004 µg/L<) | 0.005* | ||||||||
| EBV IgG | N | prokalsitonin(< 0.5 µg/L) | 2.35* | ||||||||
| EBV IgM | N | AST(<40 U/L) | 404* | ||||||||
| Weil felix test | N | ALT(<41 U/L) | 874* | ||||||||
| HIV | N | T.Bilirubine(1.2mg/dl<) | 2.06* | ||||||||
| Rickettsia conorii | N | Sedimantation(mm) | 61* | ||||||||
| HAV TOTAL | P | Amilaz(28-100 U/L) | 60* | ||||||||
| HAV IgM | N | Lipaz(13-60 U/L) | 55* | ||||||||
| Brucella | N | Protrombin time (11"-16.8") | 16.4* | ||||||||
| TPHA | N | ||||||||||
| VDRL-RPR | N | ||||||||||
Screen microorganisms were checked from the patient urine, blood and rectal swab during his stay at the infectious department. Throughout his hospital stay, determined his maximum (*) and minimum (**) laboratory findings were shown
BMI Body mass index, P Positive, N Negative, IVIG Intravenous immune globulin, LMWH Low molecular weight heparin, * = Maximum value at the given range; ** = Minimum value at the given range